Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway, discusses the development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. STEAP1 is highly expressed in prostate cancer, Ewing sarcoma, amongst other cancers and is considered an attractive target due to low expression in normal tissue, apart from the non-vital prostate gland. The STEAP1-targeting CAR-T was evaluated in vivo in both subcutaneous and metastatic xenograft mouse models of prostate cancer and is currently being developed for a clinical trial for the treatment of Ewing sarcoma. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
